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Abstract: Hyperglycemia is the main determinant of long term diabetic complications mainly through induction of oxidative 
stress responsible for secondary defects including cancer, infertility etc. Thiazolidinediones (TZDs) are known to posses 
the antioxidant potential against the reactive oxygen species. The ability of clinically used TZDs like Rosiglitazone (RSG) 
and Pioglitazone (PIO) in diabetic complications is still need to be studied extensively in the literature. In this study, the 
role of RSG and PIO on the frequency of nuclear and germinal cell damage was studied using bone marrow micronucleus 
(MN) test, sperm shape abnormality and sperm count in normal animals. The drugs were tested in the three doses (1, 10 
and 100 mg/kg) after acute (48 hrs and 72 hrs) and chronic (4 weeks) treatment. The results indicated that RSG has produced 
signiﬁ  cant (p < 0.01) decrease in P/N (polychromatic and normochromatic erythrocytes) ratio at 10 and 100 mg/kg without 
affecting the frequency of micronucleated erythrocytes, sperm shape morphology and sperm count. PIO in the tested doses 
did not induce any change in P/N ratio and sperm count but the higher dose (100 mg/kg) showed suppression of MN in 
normochromatic erythrocytes and % sperm shape abnormality compared to the control group.
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Introduction
Diabetes mellitus is one of the common metabolic diseases, affecting about 3%–5% of the world’s 
population (Ramachandran et al. 2002). Increasing evidences in both experimental and clinical studies 
suggests that there is over production of reactive oxygen species (ROS) in the diabetes. Oxidative stress 
induces a variety of lesions in DNA, including oxidized bases, DNA strand breaks and formation of 
cross-links between DNA and proteins (Baynes, 1991). Mutations that occur due to DNA damage is 
known to cause cancer, heart ailments, aging and neurological diseases. The oxidative damage to the 
germinal cells is considered to be the leading cause for the various reproductive related complications 
resulting in infertility and other congenital and developmental defects (Singh et al. 2004). The mutagenic 
tests are increasing used as a reliable tool to measure the extent of DNA damage that occurs due to the 
environmental chemicals, drugs or diseases. Among the battery of tests available, the bone marrow 
micronucleus test in rodents is a well established method to assess the nuclear damage in the host system 
(Vijaylaxmi and Venu, 1999).
The pharmacotherapy of diabetes includes administration of insulin and/or oral hypoglycemics. 
Several classes of oral anti-diabetics are used; often combinations of these agents are administered to 
control the hyperglycemia. The chronic use of some of these agents has been reported to produce 
mutagenicity (Renner and Munzner, 1980).
Peroxisome proliferator activator receptor- gamma (PPAR-γ) ligands like Thiazolidinediones (TZDs) 
are the newer generation anti-diabetic agents primarily used to improve the peripheral insulin sensitivity 
(Berger and Moller, 2002). Among the TZDs, Troglitazone was the ﬁ  rst to be approved by the USFDA, 
however it was later withdrawn from the market due to its association with severe hepatotoxicity 
(Kohlroser et al. 2000). Currently Pioglitazone (PIO) and Rosiglitazone (RSG) are the clinically used 
TZDs, both the compounds have the common thiazolidine-2-4-dione structure, differ in their side chain 
which may modify the pharmacological activity and side effects. Chemically PIO is 5-((4-(2-(5-ethyl-
2-pyridinyl) ethoxy) phenyl) methyl) – 2, 4 – thiazolidinedione (C19 H20 N2 O3 S) whereas
RSG is 5-((4-(2-(methyl – 2-pyridinylamino) ethoxy) phenyl) methyl) – 2,4 – thiazolidinedione 424
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(C18 H19 N3 O3 S) (Gillies and Dunn, 2000; Balfour 
and Plosker, 1999).
TZDs, apart from the anti-diabetic action, are 
reported to have several beneﬁ  cial applications such 
as antioxidant, anticancer, anti-inﬂ  ammatory etc 
(Saiki et al. 2007; Bao el al 2007; Galli et al. 2006; 
Chinetti et al. 2000). However, a recent study 
reveals that PIO administration for 2 weeks 
(10–40 mg/kg/day) has enhanced the DNA damage 
in rat hepatocytes and blood lymphocytes (Bedir 
et al. 2008). Similarly, in another study, RSG has 
shown increased nuclear damage in rat hepatocytes 
when it was tested daily (0.5–2.0 mg/kg) for two 
weeks (Bedir et al. 2006). Further, a product 
monograph also indicated that RSG treatment has 
produced a two-fold increase in mutations in the in 
vitro mouse lymphoma assay at toxic concentrations 
(150–200 µg/ml) (www.gsk/avandamet).
According to the OECD guidelines, the drugs 
that are used extensively and over a long duration 
of time need to be tested extensively for mutagen-
icity, carcinogenicity, teratogenicity and other 
types of complication on the host system (OECD 
guidelines for genotoxicity testing). Hence, the 
present research was planned to evaluate the role 
of clinically used TZDs on the mutagenic potential 
and to ﬁ  nd their effect on the fertility related 
changes in male Wister rats.
Materials and Methods
Chemical
A gift sample of Rosiglitazone and Piogitazone 
were obtained from Biocon (India) Ltd, Bangalore. 
The stains and other reagents/chemicals used in 
this study were of analytical grade and procured 
from the regular suppliers. The acute and chronic 
treatment of the test drugs were done according to 
the guidelines for the mammalian micronucleus 
test (MacGregor et al. 1987).
Animals
Eight week-old healthy, laboratory bred, male Wistar 
rats weighing 180 ± 10 gm were maintained under 
standard laboratory conditions such as temperature 
22–25 
oC, 12 hour light/dark cycle and provided 
water and pellet food ad libitum. The experiments 
were conducted in CPCSEA (Committee for the 
purpose of control and supervision of experiments 
on animals, Chennai, India) approved animal house 
after obtaining the prior approval from the Institutional 
Animal Ethics Committee.
Dosage, treatment and sampling
As per the guidelines to conduct the mammalian 
bone marrow micronucleus assay, at least three doses 
should be used to examine a dose-response relation-
ship (MacGregor, 1987). In our study, we observed 
that daily administration of PIO and RSG to Wistar 
rats at a dose 100 mg/kg or above, past two weeks 
has shown symptoms of hypoglycemia like shiver-
ing, impaired response to auditory, visual and tactile 
response with occasional mortality (10%). Based on 
these observations, in the present study three doses 
viz., 1, 10 and 100 mg/kg were selected, 10 mg/kg 
being the reported therapeutic concentration (Sharabi 
et al. 2007; Gaikwad et al. 2007).
Forty animals were randomly selected and 
divided in to two groups namely; treatment and 
control. The treatment group received Rosigli-
tazone (1, 10, 100 mg/kg, p.o) and Pioglitazone (1, 
10 and 100 mg/kg, p.o) suspended in 1% carboxy 
methyl cellulose (CMC). The samplings in the 
acute treatment were done after 48 hr and 72 hr. In 
the chronic group, the drugs were administered 
orally for 4 weeks and the sampling was done after 
24 hr after the last dose. The control group received 
saline (1 ml/500 gm), simultaneously a solvent 
control was also performed that received 1% CMC 
(1 ml/500 gm).
Bone marrow micronucleus (MN) test 
and scoring
The modiﬁ  ed method of Schimid was followed to 
perform the bone marrow MN test (Vijaylaxmi and 
Venu, 1999). The animals after respective treatment 
were sacriﬁ  ced by cervical dislocation under light 
anesthesia. Animals were cut open to excise femur 
and tibia. Bone marrow MN slides were prepared 
by using the modiﬁ  ed method of Schmid. Marrow 
suspension from femur and tibia bones prepared 
in 5% bovine serum albumin (BSA), was centri-
fuged at 1000 rpm for 8 min and the pellet was 
resuspended in a required quantity of BSA.
A drop of this suspension was taken on a clean 
glass slide and smear was prepared on glass slide 
and air dried. The slides were ﬁ  xed in absolute 
methanol, stained with May-Grunwald-Giemsa 
and MN were identiﬁ  ed in two forms of RBCs 
(i.e. polychromatic erythrocytes as PCEs and 
normochromatic erythrocytes as NCEs) (Plate-1). 425
Effect of thiazolidinediones on the erythropoeitic and germinal cells in the male Wistar rats
Clinical Medicine:  Oncology 2008:2 
About 2000 PCEs and corresponding NCEs were 
scanned for the presence of MN.
Sperm morphology and sperm 
count assay
The procedure described by Wyrobek and Bruce 
(1975) was followed to study the sperm shape 
abnormality. From the same sacriﬁ  ced animals, 
cauda epididymis was immediately removed and 
minced in 10 ml phosphate buffer solution (PBS, 
pH 7.2) and the suspension was ﬁ  ltered through 
muslin cloth. To the ﬁ  ltrate, one drops of 1% eosin-
Y was added and kept for 30 min for the staining 
of sperms. Smears were prepared on clean glass 
slides and air dried. One thousand sperms per 
animals were screened to ﬁ  nd the different types 
of abnormality. Five types of abnormalities such 
as amorphous, hookless, banana shape, coiled/
curved and double headed (Plate-2) were evaluated 
and finally represented as percentage total 
abnormality.
The sperm count test was performed according 
to Takizawa and Horii (2002). An aliquot of stained 
sperms solution was taken in white blood cell 
pipette up to the 0.5 mark and diluted further up 
to mark 11 with PBS. The mixture was shaken and 
charged in to the Neubauer’s chamber, the sper-
matozoal count was obtained by counting the 
number of sperm cells in the four WBC chambers 
using a neubauer’s slide.
Statistical analysis
The statistical signiﬁ  cance of the result was carried 
out using one-way ANOVA followed by Tukey 
multiple comparison test. P < 0.05 was considered 
to indicate the signiﬁ  cance of the result.
Results
Bone marrow MN test
The ability of the drug treatment to cause the 
nuclear damage was tested using the bone marrow 
MN test. The administration of RSG (1, 10 and 
100 mg/kg) in the acute treatment indicated that 
it did not cause any signiﬁ  cant increase in the 
MN frequency nor altered the P/N ratio compared 
to control. However when RSG was tested for 
4 weeks, there was signiﬁ  cant (p < 0.01) variation 
in the P/N ratio. The % reduction in P/N ratio 
was found to be 13% and 22% at 10 and 100 
mg/kg RSG treatment respectively. Additionally, 
the RSG treatment did not produce any difference 
in the number of micronucleated erythrocytes 
statistically. In the PIO group, the treatment in 
three doses did not produce any significant 
change in the P/N ratio. Conversely, PIO 
(100 mg/kg) exhibited a signiﬁ  cant (p < 0.05) 
suppression of micronuclei formation in 
normochromatic erythrocytes when compared 
with normal group (Table 1).
Plate 1. The arrow indicates micronucleated PCEs with normal NCEs.426
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Sperm shape abnormality 
and sperm count
Three doses of RSG and PIO such as 1, 10 and 
100 mg/kg were tested to assess their role on sperm 
shape abnormality and sperm count. Administration 
of RSG in these doses did not produce any 
signiﬁ  cant variation in total percentage sperm 
shape abnormality and sperm count compared to 
control. However, the treatment with PIO showed 
a dose dependent decrease in the total number of 
sperm abnormality and the signiﬁ  cant (p < 0.05) 
effect was observed at PIO 100 mg/kg dose. The 
treatment of PIO at the three doses tested did not 
affect the caudal sperm count (Table 2).
Discussion
Bone marrow MN test in rodents is a established 
model to evaluate the cytogenetic damages caused 
by chemical and environmental mutagens. The 
induction of MN is studied in two forms of 
erythrocytes namely polychromatic and normo-
chromatic erythrocytes to minimize the chances of 
counting artifacts as MN (Vijaylaxmi and Venu, 
1999). Polychromatic erythrocytes are the 
immediate enucleated cells which still posses some 
nuclear material in the cytoplasm, enabling it to 
retain the nuclear stain. While normochromatic 
erythrocytes are the mature RBCs, devoid of the 
nuclear component, due to which they do not retain 
the nuclear stain during washing (Krishna and 
Hayashi, 2000). The ratio of P/N in normal 
condition is 1:1, decrease in the P/N ratio indicates 
the ability of the drugs to interfere in the cell cycle 
and inhibition in the proliferation of erythrocytes 
(Vijaylaxmi and Venu, 1999).
The present study indicated that RSG has shown 
signiﬁ  cant reduction in P/N ratio and did not affect 
the MN frequency, sperm shape morphology and 
sperm count. On the other hand, PIO produced a 
signiﬁ  cant decrease in the total percentage sperm 
abnormality without inducing any change in sperm 
count, micronucleated erythrocytes population and 
P/N ratio.
Earlier studies reveal that RSG induces cell 
growth arrest or death in normal and cancer cells. 
The possible mechanism suggested include that 
RSG inhibit the cancer cell growth in part through 
Plate 2. Represents different types of sperm shape abnormality.427
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the activation of TSC2 (Tuberin) with the subsequent 
suppression of m TOR (molecular target of 
rapamycin) signaling (Sugimura et al. 1999; Hans 
et al. 2007). There have been reports that RSG might 
also cause disruptions in the cellular integrity by 
interfering in the transmembrane potential (Haskins 
et al. 2001). Involvement of similar mechanism in 
this study could have caused the suppression of 
proliferation of erythrocytes resulting in diminished 
P/N ratio. Further, a genotoxic study conducted on 
RSG indicated that exposure of rats to RSG has 
caused DNA damage largely in the liver cells. The 
authors suggest that generation of free radicals due 
to the cytochrome-mediated oxidation reactions 
could be the basis for the RSG induced nuclear 
damage (Bedir A et al. 2006). However, in the 
present work, RSG has not induced any nuclear 
damage as the frequency of MN erythrocytes did 
not increase signiﬁ  cantly, indicating that RSG at the 
tested doses is non-mutagenic. In addition, the 
previous reports indicate that RSG in a series of in 
vivo and in vitro tests including the bacterial 
assays was found to negative for the gene mutation 
(www.gsk/avandamet).
Recently, a study conducted to evaluate the 
genotoxic potential of PIO indicated that the daily 
treatment of PIO to rats has increased the % tail 
DNA in hepatocytes and lymphocytes. Enhance-
ment in the oxidative stress due to generation of 
free radicals from the mitochondrial and/or extra 
mitochondrial sources was considered as the pos-
sible reason for the PIO mediated nuclear damage 
(Bedir et al. 2008). However, several studies in the 
past have reported that TZDs posses potent anti-
oxidant property. Both RSG and PIO are known 
to exhibit the antioxidant effect against free radi-
cals by enhancing the endogenous antioxidant 
enzyme defence (Gumieniczek, 2005; Saiki et al. 
2007; Bao et al. 2007). The ability of RSG and PIO 
to induce the DNA damage in the liver cells could 
be because; TZDs are primarily metabolized in 
liver by CYP P-450 enzymes, the oxidative stress 
that occurs due to the metabolism might have 
produced the localized damage to the hepatocytes 
DNA. However the PIO induced nuclear damage 
to the lymphocytes need to be further studied, 
especially in the context that TZDs are recognized 
to counteract the reactive oxygen species.
In this study, PIO did not produce any signiﬁ  -
cant change in the P/N ratio. Moreover, administra-
tion of PIO (100 mg/kg) has reduced the number 
of micronucleated normochromatic erythrocytes 
compared to the control group. The ability of PIO 
to minimize the chromosomal damage can be 
attributed to its antioxidant property since inhibition 
in the free radicals action is known to suppress the 
nuclear damage (Saiki et al. 2007).
The cytonuclear damage to the reproductive 
cells results in infertility. In males, these damages 
cause both qualitative and quantitative defects in 
the spermatozoal cells. Changes in the sperm mor-
phology not only decrease the fertility rate but also 
cause several developmental and birth defects 
(Singh et al. 2004). The oxidative stress due to the 
hyperglycemia is the principle factor in the diabetic 
patients responsible for the variation in sperm 
morphology and count. In addition, the chances of 
further increase in the damage due to the chronic 
administration of anti-diabetic agents can have 
negative impact on the patient physical and mental 
health (Kumar et al. 2002). Therefore, it becomes 
extremely imperative to test this category of drugs 
for their role on fertility. In this study, the tested 
doses of RSG and PIO after acute and chronic 
treatment did not show signiﬁ  cant variation in the 
percentage sperm shape abnormality and sperm 
count. However, PIO at the highest tested dose 
(100 mg/kg) produced a signiﬁ  cant reduction in 
the number of defective sperms. PIO in the earlier 
studies have been reported to enhance the level of 
antioxidant status (Saiki et al. 2007), this property 
of PIO, in this study too could have counteracted 
the actions of free radicals leading to decreased 
number of abnormal sperms.
Compounds possessing anti-proliferative and 
antidiabetic effects can be beneficial to the 
diabetic patients suffering from cancer (Galli 
et al. 2006). However, the data from the recent 
ﬁ  ndings suggest that both RSG and PIO have the 
potential to cause genotoxic damage. These 
observations emphasis the need to test the safety 
of RSG and PIO by other battery of mutagenic 
tests, since many diabetic patients still use 
them to control the insulin resistance related 
complications world wide.
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